TEV-56278 clinical trials

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This study is testing a new cancer medicine, TEV-56278, on its own and with another medicine called pembrolizumab, for people with advanced solid tumours. Researchers want to see if it's safe, what dose works best, and if it can shrink tumours.